Internal Polymeric Vessel Occluder for Temporary Vascular Occlusion of the Kidney

Information

  • Research Project
  • 7611799
  • ApplicationId
    7611799
  • Core Project Number
    R44DK079481
  • Full Project Number
    2R44DK079481-02
  • Serial Number
    79481
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    7/16/2009 - 15 years ago
  • Project End Date
    6/30/2011 - 13 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    7/16/2009 - 15 years ago
  • Budget End Date
    6/30/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/16/2009 - 15 years ago
Organizations

Internal Polymeric Vessel Occluder for Temporary Vascular Occlusion of the Kidney

DESCRIPTION (provided by applicant): Two important advances in the treatment of renal cancer are gaining acceptance;partial nephrectomy is replacing radical nephrectomy for preserving functioning renal tissue, and minimally invasive surgery is replacing open partial nephrectomy. For both, control of intra-operative renal bleeding is essential. Pluromed has developed a family of Rapid Transition Polymers" (RTPs"), reverse thermosensitive polymers which are liquid at low temperatures and rapidly transition to gel as they warm to body temperature. The aqueous polymer is reversible back to a liquid via cooling and is dissolvable. The Company has developed a new RTP, LeGoo-XL", and a technique, Perfusive Hemostasis", which are used to achieve superior hemostasis during partial nephrectomy. By injecting LeGoo-XL into a segmental branch of the renal artery, blood flow is reversibly interrupted to that renal segment destined for resection while normal flow is maintained to uninvolved s commercialization by performing all of the pre-clinical development required in anticipation of a subsequent clinical trial supporting FDA approval. This includes validation and extension of Phase I results, a comparison of LeGoo-XL to standard arterial clamping techniques, an assessment of the safety and biocompatibility of the polymer, and development of a market-ready injection system. Acute and chronic experiments in pigs and calves will be performed. The Specific Aims of this project are: 1. To verify and extend Phase I results in an acute pig study;2. To compare LeGoo-XL to renal artery clamping in acute and chronic pigs;3. To study pathology in 6 week survival pigs;4. To extend results to a second and larger animal model in an acute calf study;5. To characterize the biocompatibility, toxicity and physiochemistry of LeGoo-XL;6. To develop a market-ready angiographic injector and system 7. To develop an alternative direct renal artery injection technique upon completion ofinimally invasive techniques in this approach by offering superior hemostasis and allowing surgery on one section of the kidney while maintaining normal flow to the remaining renal tissue. PUBLIC HEALTH RELEVANCE: Surgically removing only the morbid part of a diseased kidney instead of removing the entire kidney, nephron- sparing surgery, is beneficial for long-term kidney function. The technical hurdles limiting the adoption of this approach are the ability to control bleeding during the surgery and the need to reduce warm ischemia time. A bloodless field is vital to the success of minimally invasive techniques. LeGoo-XL offers superior hemostasis and the ability to temporarily interrupt flow only to that renal segment destined for resection. This approach has the capability to make the surgeon's job easier and the partial nephrectomy procedure shorter while leading to better renal function and outcomes. It has the potential to enable greater adoption of both the partial nephrectomy approach and the use of minimally invasive techniques in this approach.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    636620
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:636620\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PLUROMED, INC.
  • Organization Department
  • Organization DUNS
    188416809
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018016379
  • Organization District
    UNITED STATES